Lotus Pharmaceuticals

Lotus Pharmaceuticals es propiedad de Alvogen. Alvogen tiene presencia directa en 4 países.

Alvogen posee 5 subsidiarias incluyendo Adalvo, Alvogen Americas y Alvogen APAC.

Ellos se encuentran en:

• Farmacia83%
• Biotecnología17%

Ver el organigrama con sus 26 ejecutivos principales

Biografías más buscadas en Lotus Pharmaceuticals

• Petar Vazharov, General Manager and Director
• Krisana Winitthumkul, Director
• Yves Hermes, Director

Crear su alerta
para seguir los movimientos de los ejecutivos en Lotus Pharmaceuticals.

Alvogen tiene 1.860 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).

Popular M&A news in Farmacia

• MedMen has filed for bankruptcy protection  (publicado el 28 de abril de 2024).
• AstraZeneca has announced the acquisition of Fusion Pharma  (publicado el 23 de marzo de 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (publicado el 19 de marzo de 2024).

Otros contactos sugeridos en el sector Farmacia

• Jean-Frédéric Paulsen - Executive Chairman of the Board en Ferring Pharmaceuticals
• Thierry Abribat - Chief Executive Officer en Amolyt Pharma
• Emma Walmsley - Chief Executive Officer and Director en GSK

Saber más sobre el sector Farmacia >

Últimos comunicados de prensa de Lotus Pharmaceuticals

• Lotus marked historical high for 2023 revenues, profit and cash dividend - Lotus
• Lotus Reported Unaudited February Revenues of NT$1,052 Million - Lotus
• Lotus Reported Unaudited January Revenues of NT$1,996 Million, surging 45.4% MoM - Lotus
• Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 million, showcasing MoM and YoY Growth 2023 Unaudited Consolidated Revenues Grew 16% to NT$16,958 million, marking 5th consecutive year of double-digit growth - Lotus
• Lotus and Favorex Pte Ltd Announces Strategic Partnership to Commercialize an Ustekinumab Biosimilar in South Korea - Lotus
• Lotus Pharmaceutical Announces First Shipment of Lenalidomide to Japan - Lotus
• Lotus Achieves Historic Q3 2023 Results with YTD EPS Soaring to a Record NTD 14.19 Marking a 29% Year-on-Year Growth - Lotus
• Lotus and Intas Announce Strategic Partnership to Commercialize Denosumab Biosimilar in Asia - Lotus
• Lotus Reported Unaudited November Consolidated Revenues of NT$1,135 million, representing 25% MoM Growth and 6% YoY Growth - Lotus
• Lotus Hosts Third Quarter 2023 Results Investor Conference - Lotus
• View more press releases Close

Redes sociales sobre Lotus Pharmaceuticals

• Lotus Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Lotus Pharmaceuticals en LinkedIn, Twitter y YouTube

Contactar a través de e-mail con sus ejecutivos Petar Vazharov

Llame a Lotus Pharmaceuticals al +886 22...

Ver el organigrama

Register to receive your alert

Señalar un error